Initially, the Japanese firm will develop NBI-98854 in Japan for the chorea associated with Huntington’s disease (HD) and tardive dyskinesia. Complete commercial rights to NBI-98854 in North America,
DDD107498 was developed as part of a collaboration between MMV and the University of Dundee Drug Discovery Unit, led by Prof Ian Gilbert and Dr Kevin Read. The
Due to the potential risk of osteosarcoma, Natpara is indicated only for patients who cannot be well-controlled on calcium supplements and active forms of vitamin D alone. The
The drug is indicated for use in children and adolescents from four years of age who have had an inadequate response to or are inappropriate candidates for topical
Currently, the company is conducting a clinical trial of IMO-8400 in patients with relapsed or refractory DLBCL harboring MYD88 L265P oncogenic mutation. The company said that preclinical trials
UCB’s established products business will cover the territories of India, Nepal, Sri Lanka and Maldives. The acquisition of UCB’s existing established brands in India, including its franchises in
In order to close the merger, Valeant offered a $173 per Salix share, which is an increase from a bid of $158 per share in cash made this
Propafenone is indicated to prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. Additionally, it is indicated
BCX4430 is an RNA dependent-RNA polymerase inhibitor that has showed broad-spectrum activity in vitro against more than 20 RNA viruses in nine different families such as filoviruses, togaviruses,
Amlodipine and Valsartan Tablets are the generic version of Swiss pharmaceutical firm Novartis’ Exforge Tablets. The US Food and Drug Administration (FDA) has also granted approval for the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.